Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma

John H. Chen, Daniel J. Lenihan, MD, Sharon E. Phillips, MSPH, Madan H. Jagasia, Stacey A. Goodman, MD MS, Adetola A. Kassim, MD MS, Shelton L. Lacy, Kevin T. McDonagh, Javid J. Moslehi, MD, Tarsheen K. Sethi, MD MS, David A. Slosky, Oluchi C. Ukaegbu, MD, Robert F. Cornell

Blood (2015) 126 (23): 5363.

https://doi.org/10.1182/blood.V126.23.5363.5363

Published: 2015

Journal Articles

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Blood (2012) 119 (24): 5661–5670.

https://doi.org/10.1182/blood-2012-03-414359

Published: 2012

Journal Articles

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Blood (2011) 118 (21): 813.

https://doi.org/10.1182/blood.V118.21.813.813

Published: 2011

Journal Articles

Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237)–An Investigational Aurora A Kinase Inhibitor–in Patients with Advanced Hematologic Malignancies

Kevin R. Kelly, MD, Swaminathan Padmanabhan, MBBS, MD, André Goy, MD, Jesus G. Berdeja, MD, Craig B. Reeder, MD, Kevin T. McDonagh, MD, Xiaofei Zhou, PhD, Hadi Danaee, SD, Hugh Xiao, PhD, Ely Benaim, MD, Thomas C. Shea, MD

Blood (2011) 118 (21): 2477.

https://doi.org/10.1182/blood.V118.21.2477.2477

Published: 2011

Journal Articles

Phase I Study of An Investigational Aurora A Kinase Inhibitor MLN8237 In Patients with Advanced Hematologic Malignancies.

Swaminathan Padmanabhan, MBBS, MD, Thomas C. Shea, MD, Julie M. Vose, MD, Craig B. Reeder, MD, Jesus G Berdeja, MD, Kevin T. McDonagh, MD, Andre Goy, MD, Kevin R Kelly, MD, Xiaofei Zhou, PhD, Hua Liu, PhD, Howard Fingert, MD, Nathan Fowler, MD

Blood (2010) 116 (21): 2799.

https://doi.org/10.1182/blood.V116.21.2799.2799

Published: 2010

Journal Articles

Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients

Ravi Vij, MBBS, MD, Jonathan L. Kaufman, MD, Andrzej J Jakubowiak, MD, PhD, A. Keith Stewart, MBChB, Sundar Jagannath, MD, Vishal Kukreti, MD, FRCPC, Kevin T. McDonagh, MD, Melissa Alsina, MD, Nizar J Bahlis, MD, Andrew Belch, MD, Frederic J. Reu, MD, Nashat Y Gabrail, MD, Jeffrey Matous, MD, David H. Vesole, MD, PhD, Robert Z. Orlowski, MD, PhD, Mai H. Le, MD, Peter Lee, MD, PhD, Michael Wang, MD, The MMRC

Blood (2010) 116 (21): 1938.

https://doi.org/10.1182/blood.V116.21.1938.1938

Published: 2010

Journal Articles

Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ).

Andrzej Jakubowiak, MD, PhD, Luhua Wang, MD, Robert Z Orlowski, M.D., Ph.D., Sundar Jagannath, MD, David Siegel, A. Keith Stewart, MD, Vishal Kukreti, MD, FRCPC, Sagar Lonial, MD, Kevin T. McDonagh, MD, Marcy Vallone, Michael Kauffman, MD, PhD, Ravi Vij, MD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2009) 114 (22): 1827.

https://doi.org/10.1182/blood.V114.22.1827.1827

Published: 2009

Journal Articles

Inhibition of the Proteasome in Bone Marrow-Derived CD138+ Tumor Cells Following Carfilzomib Administration in Relapsed or Refractory Myeloma Patients.

Suzanne Trudel, MD, Susan Lee, Christopher J. Kirk, PhD, Nashat Gabrail, MD, Sagar Lonial, MD, Luhua Wang, MD, Robert Z Orlowski, M.D., Ph.D., Vishal Kukreti, MD, FRCPC, A. Keith Stewart, MD, Sundar Jagannath, MD, Kevin T. McDonagh, MD, Francis Buadi, MD, Jeffrey A Zonder, MD, Mark K Bennett, PhD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2009) 114 (22): 1845.

https://doi.org/10.1182/blood.V114.22.1845.1845

Published: 2009

Journal Articles

Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).

Luhua Wang, MD, David Siegel, Jonathan L. Kaufman, MD, A. Keith Stewart, MD, Andrzej J Jakubowiak, MD, PhD, Melissa Alsina, MD, Vishal Kukreti, MD, FRCPC, Nizar J Bahlis, MD, Kevin T. McDonagh, MD, Andrew Belch, MD, Michael Sebag, MD, PhD, Nashat Gabrail, MD, Mai H. Le, MD, Mark K Bennett, PhD, Lori Kunkel, MD, Michael Kauffman, MD, PhD, Robert Z Orlowski, M.D., Ph.D., Ravi Vij, MD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2009) 114 (22): 302.

https://doi.org/10.1182/blood.V114.22.302.302

Published: 2009

Journal Articles

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.

David Siegel, Luhua Wang, MD, Robert Z Orlowski, M.D., Ph.D., Jonathan L. Kaufman, MD, A. Keith Stewart, MD, Vishal Kukreti, MD, FRCPC, Melissa Alsina, MD, Andrzej J Jakubowiak, MD, PhD, Sundar Jagannath, MD, Kevin T. McDonagh, MD, Andrew Belch, MD, Nizar J Bahlis, MD, Chaim Shustik, MD, Mai H. Le, MD, Lori Kunkel, MD, Mark K Bennett, PhD, Michael Kauffman, MD, PhD, Ravi Vij, MD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2009) 114 (22): 303.

https://doi.org/10.1182/blood.V114.22.303.303

Published: 2009

Journal Articles

Phase I Study of the Novel Surivin and cdc2/CDK1 Inhibitor Terameprocol in Patients with Advanced Leukemias.

Raoul Tibes, MD, PhD, Kevin T. McDonagh, MD, Lazaros Lekakis, MD, Neal Frazer, MD, Scott Mohrland, PhD, Bassett Dawn, RN, Reynaldo Garcia, RN, OCN, Katy Schroeder, RN, Vijayalakshmi Shanmugam, John Carpten, Daniel Von Hoff, MD, FACP, Thomas C. Shea, MD

Blood (2009) 114 (22): 1039.

https://doi.org/10.1182/blood.V114.22.1039.1039

Published: 2009

Journal Articles

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study

Blood (2007) 110 (4): 1388–1396.

https://doi.org/10.1182/blood-2007-02-072389

Published: 2007

Journal Articles

Four-Year Follow-Up after High-Dose Immunosuppressive Therapy (HDIT) for Severe Systemic Sclerosis (SSc).

Richard A. Nash, Peter McSweeney, Leslie Crofford, Kevin T. McDonagh, Maureen Mayes, J. Lee Nelson, Ted Gooley, Leona Holmberg, Howard Shulman, Mark Wener, Bernadette McLaughlin, Gretchen Henstorf, Jerry Molitor, James Seibold, Keith Sullivan, Daniel Furst

Blood (2006) 108 (11): 3071.

https://doi.org/10.1182/blood.V108.11.3071.3071

Published: 2006

Journal Articles

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes

Peter A. McSweeney, Richard A. Nash, Keith M. Sullivan, Jan Storek, Leslie J. Crofford, Roger Dansey, Maureen D. Mayes, Kevin T. McDonagh, J. Lee Nelson, Theodore A. Gooley, Leona A. Holmberg, C. S. Chen, Mark H. Wener, Katherine Ryan, Julie Sunderhaus, Ken Russell, John Rambharose, Rainer Storb, Daniel E. Furst

Blood (2002) 100 (5): 1602–1610.

https://doi.org/10.1182/blood.V100.5.1602.h81702001602_1602_1610

Published: 2002

NARROW

Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237)–An Investigational Aurora A Kinase Inhibitor–in Patients with Advanced Hematologic Malignancies

Phase I Study of An Investigational Aurora A Kinase Inhibitor MLN8237 In Patients with Advanced Hematologic Malignancies.

Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients

Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ).

Inhibition of the Proteasome in Bone Marrow-Derived CD138+ Tumor Cells Following Carfilzomib Administration in Relapsed or Refractory Myeloma Patients.

Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.

Phase I Study of the Novel Surivin and cdc2/CDK1 Inhibitor Terameprocol in Patients with Advanced Leukemias.

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study

Four-Year Follow-Up after High-Dose Immunosuppressive Therapy (HDIT) for Severe Systemic Sclerosis (SSc).

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only